Stocktoria
Samsung Biologics Co.,Ltd. 207940.KS
Samsung Biologics Co.,Ltd. (207940.KS) earns a Piotroski F-score of 9/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $4.56T at a 39.2% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 36 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 9/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.17 |
| Retained earnings / assets | 0.621 |
| EBIT / assets | 0.187 |
| Equity / liabilities | 2.064 |
FAQ
Is 207940.KS financially healthy?
Samsung Biologics Co.,Ltd.'s Piotroski F-score is 9/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does 207940.KS pay a dividend?
No, Samsung Biologics Co.,Ltd. does not currently pay a dividend.
How profitable is 207940.KS?
In FY2025, Samsung Biologics Co.,Ltd. had a net margin of 39.2% and a return on equity of 23.9%.
Source: company filings via Yahoo Finance · KR · as of 2025-12-31. Figures in KRW; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.